Boryung to Take Charge of Domestic Sales and Marketing for 'Atojet'... Expanding Presence in the Dyslipidemia Market

Signing of Atojet Co-Promotion Agreement

Expanding Portfolio Beyond Hypertension

Boryung will now not only handle domestic distribution of Organon Korea's dyslipidemia medication 'Atojet,' but will also be responsible for sales and marketing. By leveraging its sales network established in the field of chronic disease, the company aims to expand its influence in the dyslipidemia market.

(From left) Kim Jungkyun, CEO of Boryung, and Kim Soeun, CEO of Korean Organon, are taking a commemorative photo at the 'Atozet Joint Sales and Distribution Contract Signing Ceremony.' Boryung

On September 16, Boryung and Organon Korea announced that they have signed a co-promotion agreement for the joint sales and marketing of Atojet (active ingredients: ezetimibe and atorvastatin), a treatment for dyslipidemia, in Korea. Since August 1, Boryung has been responsible for Atojet’s domestic distribution, and as of this month, the scope of collaboration has been expanded to include sales and marketing.

Under this agreement, both companies will jointly conduct sales and marketing activities for Atojet and provide information about dyslipidemia treatment and the product to healthcare professionals in Korea.

Atojet is a combination therapy for dyslipidemia that combines ezetimibe, which inhibits cholesterol absorption, and atorvastatin, a statin-class agent. The product comes in four dosage strengths, allowing for prescriptions to be tailored to the patient's risk level and LDL cholesterol (LDL-C) treatment goals.

Notably, among ezetimibe-atorvastatin combination drugs, Atojet is available in the highest dosage combination of ezetimibe 10mg and atorvastatin 80mg. Recently, clinical evidence was also obtained from the BETTER study regarding the effectiveness of achieving LDL-C target goals compared to atorvastatin monotherapy.

Boryung has built its sales network in the cardiovascular and metabolic disease sector with its own antihypertensive drug 'Kanarb' and related product line, the 'Kanarb Family.' The company plans to use this Atojet co-promotion to broaden its chronic disease portfolio, which has focused primarily on hypertension, into the dyslipidemia sector and strengthen its sales contact points with healthcare institutions.

Kim Jungkyun, CEO of Boryung, stated, "This co-promotion expands the scope of collaboration from distribution to sales and marketing, combining the strengths of both companies. By leveraging our strength on the sales front, we will strengthen Atojet’s position in the market and broaden Boryung’s influence in the dyslipidemia field."

Kim Soeun, CEO of Organon Korea, said, "As the number of dyslipidemia patients in Korea continues to rise, the importance of achieving aggressive treatment goals and systematic management is also increasing. Based on the expertise and strengths of both companies, we will effectively provide healthcare professionals with information about Atojet and dyslipidemia treatment."

This content was produced with the assistance of AI translation services.